This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. N completed  692  631  594  415  498  478  470  571  541  528  497  423  362  197  59   N expected  916  907  901  898  894  891  882  877  865  842  807  752  588  317  84   %of those  expected  76%  70%  66%  46%  56%  54%  53%  65%  63%  63%  62%  56%  62%  62%  70%   six  months of  treatment   N completed  695  599  591  543  509  457  186  497  541  512  492  408  341  191  58   N expected  912  902  895  889  886  884  878  873  862  848  815  761  617  319  86 %of those expected 76% 66% 66% 61% 57% 52% 21%* 57% 63% 60% 60% 54% 55% 60% 67% *Low return rate because patients assessed at start of last cycle rather than 6 months (which corresponds to end of cycle) Note that although results are available beyond year 6 they have been omitted because of small numbers and resultant wide confidence intervals 
23%* 63%582/916 67% *Low return rate because patients assessed at start of last cycle rather than 6 months (which corresponds to end of cycle) N completed  692  631  594  415  498  478  470  571  541  528  497  423  362  197  59   N expected  916  907  901  898  894  891  882  877  865  842  807  752  588  317  84   %of those  expected  76%  70%  66%  46%  56%  54%  53%  65%  63%  63%  62%  56%  62%  62%  70%   six  months of  treatment   N completed  695  599  591  543  509  457  186  497  541  512  492  408  341  191  58   N expected  912  902  895  889  886  884  878  873  862  848  815  761  617  319  86 %of those expected 76% 66% 66% 61% 57% 52% 21%* 57% 63% 60% 60% 54% 55% 60% 67% *Low return rate because patients assessed at start of last cycle rather than 6 months (which corresponds to end of cycle) Note that although results are available beyond year 6 they have been omitted because of small numbers and resultant wide confidence intervals Figure 4 : Difference in quality of life scales between patients with "Quite a bit"/"Very much" numbness, tingling or discomfort in hands or feet on GOG NTX4 toxicity questionnaire and those who rated these symptoms as being present "Somewhat"/"A little bit" or "Not at all" EQ-5D self rated VAS EQ-5D 3L Health index EORTC global quality of life 1. Those where the difference in standardised adjusted AUC was statistically significant at 5% after adjustment for multiple testing 2. 3 month arm-6 month arm It can be seen that the reasons are broadly similar between the study arms with the most common reason being "other". Examination of a random sample of the free text on the CRF's when the reason for "other" was entered indicates that in the vast majority of cases this was an error of some sort (form not returned, site error, patient forgot etc.). The high proportion of "not required" for GOG-NTX4 is due to administrative delay in implementing the amendment to extend the recording period for the questionnaire. The table above shows the %-age missing for the PRO questionnaires across baseline patient characteristics. It can be seen that the percentage missing is very similar across the categories of the baseline characteristics with the difference being in general very small and never exceeding 5%. The tables above summarises the comparison of the three most important PRO end-points at key time-points. The first column is taken from the imputation analysis as presented in the paper, the second column is based on observed data and the last column is based on an imputation restricted to patients who completed a baseline questionnaire. This last analysis was done to ensure that the analysis set could not be influenced by a patient's subsequent experience on the study (for example patients who should have completed at baseline but were missed and subsequently completed a follow-up form because they developed neurotoxicity are omitted from this analysis).
At all time-points the mean differences are similar and completely consistent in terms of statistical significance. 
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